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S12 Journal of Thoracic Oncology Vol. 11 No. 2Slung tumor formation in Type II cells. Finally, using an in
vitro 3D tumor sphere culture system derived from Kras
activated Type II cells, we discovered small molecules
that speciﬁcally inhibit KrasG12D driven tumor sphere
formation by differentiation of Type II cells to Kras-resis-
tant proximal cells. Our ﬁndings could provide new ther-
apeutic strategies to target Kras-activated lung cancer by
either blocking Type II cell dedifferentiation or promot-
ing Type II cell proximalization.Adenocarcinoma indolence and
progression: Biological basisCharles A. Powell Icahn School of Medicine at
Mount Sinai, New York, NYLung adenocarcinoma can progress from an indolent in
situ carcinoma to an invasive, aggressive, metastatic tu-
mor. The WHO/IASLC/ATS Lung adenocarcinoma clas-
siﬁcation emphasizes the distinction of adenocarcinoma
in situ (AIS) and minimally invasive adenocarcinoma
from their invasive counterparts. Molecular biomarkers
of invasion can distinguish invasive from non-invasive
tumors, a distinction that is typically difﬁcult to make in
small biopsies and cytology specimens and is becoming
increasingly important as the recognition of early stage
adenocarcinoma increases with the widespread imple-
mentation of lung cancer screening programs in the
United States.
The early stage in tumor progression to a state of
invasiveness and metastasis is characterized by epithe-
lial dysregulation and instability that drives loss of
cellular adhesion and increased cell mobility and pro-
liferation. In many cases, signaling pathways important
in lung development are critical for mediating these
processes. The biological processes required for this
progression include alterations in the TGF-Beta signaling
pathway, and genomic copy number alterations of CDK4
and MDM2, and mutations in key oncogenic regulators.
Equally important in mediating adenocarcinoma
progression is the contribution by the tumor micro-
environment. The microenvironment is a complex
system comprised of stromal ﬁbroblasts, macro-
phages, lymphocytes, other bone marrow-derived
cells (BMDCs), and extracellular matrix (ECM) that in
a reciprocal fashion, can contribute to tumor regres-
sion or progression. Key regulators of the tumor
microenvironment regulation of tumor progression
include the TGF-Beta signaling pathway, thrombo-
spondin-1 (Tsp-1), and the composition of the tumor
immune contexture.
Taken together, these advances in the understanding
of tumor mediated and microenvironment mediatedprocesses that regulate adenocarcinoma progression and
metastasis will drive advances in translational ap-
proaches to improve diagnosis and treatment of lung
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Small cell lung cancer (SCLC) is a neuroendocrine
subtype of lung cancer characterized by fast growth,
early dissemination, and rapid chemotherapy resis-
tance. We identiﬁed a population of long-term, tumor-
propagating cells (TPCs) in a genetically engineered
mouse model of SCLC. This population, marked by high
levels of the EpCAM and CD24 cell surface proteins, is
also prevalent in human primary SCLC tumors derived
from circulating tumor cells (CTCs). SCLC TPCs are
numerous and highly proliferative but not intrinsically
chemoresistant, indicating that not all the clinical fea-
tures of SCLC tumors can be linked to TPCs. SCLC TPCs
possess a distinct transcriptional compared to non-
TPCs, including increased neuroendocrine features and
elevated MYC activity. Importantly, genetic and phar-
macological inhibition of MYC in mouse and human
SCLC cells to non-TPC levels inhibits long-term propa-
gation but not short-term growth. These studies iden-
tify a highly tumorigenic population of SCLC cells in
mouse models, cell lines and patient CTCs. In addition,
this work provides a rationale for therapeutic strategies
aimed to reduce the activity of MYC and other possible
oncogenic drivers to eradicate SCLC TPCs, thus specif-
ically preventing the maintenance and the spread of
this aggressive disease while minimizing harmful ef-
fects on the rest of the organism.Predictive biomarkers for
immunotherapy in lung cancer:
Opportunities and challengesKurt Schalper Yale School of Medicine, New
Haven, CTThe success achieved with the use of novel immunosti-
mulatory therapies targeting the inhibitory checkpoints
